Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Up 10.5% – What’s Next?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was up 10.5% during mid-day trading on Monday . The company traded as high as $23.90 and last traded at $23.46. Approximately 22,282 shares changed hands during trading, a decline of 92% from the average session volume of 289,093 shares. The stock had previously closed at $21.23.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Evercore initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target on the stock. HC Wainwright began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They set a “buy” rating and a $45.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Performance

The company’s 50-day moving average is $23.98 and its 200-day moving average is $25.57. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -4.11 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently modified their holdings of DMRA. Janus Henderson Group PLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $40,000. Virtu Financial LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Two Sigma Investments LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $76,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $100,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.